{"id":34983,"date":"2024-01-30T09:47:50","date_gmt":"2024-01-30T08:47:50","guid":{"rendered":"https:\/\/www.abcsg.org\/veroeffentlichungen\/publications\/publikationen-der-abcsg-2024-2023\/"},"modified":"2026-02-24T12:59:45","modified_gmt":"2026-02-24T11:59:45","slug":"abcsg-publications-peer-reviewed-2024-2023","status":"publish","type":"page","link":"https:\/\/www.abcsg.org\/en\/veroeffentlichungen\/publications\/abcsg-publications-peer-reviewed-2024-2023\/","title":{"rendered":"ABCSG-Publications (peer reviewed) 2024-2023"},"content":{"rendered":"
\n
<\/span>2024<\/div>
\n

Evolving treatment paradigms after CDK4\/6 inhibitors in advanced breast cancer
\nPosition paper on optimized sequencing<\/h4>\n

Michael Gnant, Marija Balic, Christian F. Singer, Gabriel Rinnerthaler, Georg Pfeiler, Christoph Suppan, Birgit Gr\u00fcnberger, Kathrin Strasser-Weippl, Vanessa Castagnaviz, Sonja Heibl, Rupert Bartsch<\/p>\n

memo – Magazine of European Medical Oncology
\nPublished:\u00a020 December 2024
\nhttps:\/\/doi.org\/10.1007\/s12254-024-01012-5<\/a><\/p>\n

\n

Axillary Surgery in Breast Cancer \u2014 Primary Results of the INSEMA Trial<\/h4>\n

T. Reimer, A. Stachs, K. Veselinovic, T. Kuhn, J. Heil, S. Polata, F. Marme, T. Muller, G. Hildebrandt, D. Krug, B. Ataseven, R. Reitsamer, S. Ruth, C. Denkert, I. Bekes, D.-M. Zahm, M. Thill, M. Golatta, J. Holtschmidt, M. Knauer, V. Nekljudova, S. Loibl, and B. Gerber<\/p>\n

Published on December 12, 2024, at NEJM.org.
\nhttps:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2412063<\/a><\/p>\n

\n

Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial<\/h4>\n

Alexios Matikas, Andri Papakonstantinou, Sibylle Loibl , G\u00fcnther G. Steger, Michael Untch, Hemming Johansson, Nikos Tsiknakis, Mats Hellstr\u00f6m, Richard Greil, Volker M\u00f6bus, Michael Gnant, Jonas Bergh, Theodoros Foukakis<\/p>\n

THE LANCET Regional Health \u2013 Europe
\nVolume 49 101162, February 2025
\nPublished Online 03 December 2024
\nhttps:\/\/doi.org\/10.1016\/j.lanepe.2024.101162<\/a><\/p>\n

\n

Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine<\/h4>\n

Viktoria Kn\u00f6bl,\u00a0Lukas Maier,\u00a0Stefan Grasl,\u00a0Carmen Kratzer,\u00a0Felix Winkler,\u00a0Vanessa Eder,\u00a0Hubert Hayden,\u00a0Maria Amparo Sahagun Cortez,\u00a0Monika Sachet,\u00a0Rudolf Oehler,\u00a0Sophie Frantal,\u00a0Christian Fesl,\u00a0Karin Zehetner,\u00a0Georg Pfeiler,\u00a0Rupert Bartsch,\u00a0Florian Fitzal,\u00a0Christian F. Singer,\u00a0Martin Filipits,\u00a0Michael Gnant\u00a0&\u00a0Christine Brostjan\u00a0<\/p>\n

Journal of Translational Medicine (2024) 22:913
\nhttps:\/\/doi.org\/10.1186\/s12967-024-05659-w<\/a><\/p>\n

\n

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155\u2008746 women in 151 trials<\/h4>\n

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)<\/p>\n

The Lancet 404, 10461, 1407-1418 (2024)
\nhttps:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(24)01745-8\/fulltext<\/a><\/p>\n

\n

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42\/AFT-05\/BIG-14\u201313\/PrE0109)<\/h4>\n

Guilherme Nader-Marta,\u00a0Christian Singer,\u00a0Dominik Hlauschek,\u00a0Angela DeMichele,\u00a0Paolo Tarantino,\u00a0Evandro de Azambuja,\u00a0Georg Pfeiler,\u00a0Miguel Martin,\u00a0Justin M. Balko,\u00a0Zbigniew Nowecki,\u00a0Marija Balic,\u00a0Adam M. Brufsky,\u00a0Arlene Chan,\u00a0Patrick G. Morris,\u00a0Tufia Haddad,\u00a0Sibylle Loibl,\u00a0Yuan Liu,\u00a0Lidija Soelkner,\u00a0Christian Fesl,\u00a0Erica L. Mayer\u00a0&\u00a0Michael Gnant\u00a0on behalf of the PALLAS groups and investigators<\/p>\n

Breast Cancer Research (2024) 26:140
\nPublished:\u00a007 October 2024
\nhttps:\/\/doi.org\/10.1186\/s13058-024-01899-2<\/a><\/p>\n

\n

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update<\/h4>\n

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick, Damien Parlier, Eric Winer, Jonas Bergh, Richard D. Gelber, Eleonora Restuccia, Young-Hyuck Im, Chiun-Sheng Huang, Florence Dalenc, Isabel Calvo, Marion Procter, Carmela Caballero, Emma Clark, Alice Raimbault, Robin McConnell, Estefania Monturus, Evandro de Azambuja, Henry L. Gomez, Judith Bliss, Giuseppe Viale, Jose Bines and Martine Piccart on behalf of the APHINITY Steering Committee and Investigators<\/p>\n

Journal of Clinical Oncology
\nVolume 42, Number 31, September 11, 2024
\nhttps:\/\/doi.org\/10.1200\/JCO.23.02505<\/a><\/p>\n

\n

Standardized Definitions for Efficacy End Points for Adjuvant Trials\u2014The Updated STEEP Criteria<\/h4>\n

Dominik Hlauschek, MSc; Christian Fesl, PhD; Michael Gnant, MD<\/p>\n

JAMA Oncology
\nPublished online September 19, 2024
\ndoi:10.1001\/jamaoncol.2024.3888<\/p>\n

\n

mFOLFOX6 versus mFOLFOX6\u00a0+ aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO\/ARO\/AIO 0214) and the ABCSG (R-06)<\/h4>\n

R.-D. Hofheinz, F. Herrle, T. Dechow, L. F. von Weikersthal, M. Welslau, S. Lettmaier , C. Burkart, S. Kubicka, L. Kochen, K. Merx, K. Krause, M. Ebert, C. R\u00f6del, E. Fokas, M. Ghadimi, C. Reissfelder & T. Gaiser<\/p>\n

ESMO Open
\nVolume 9,\u00a0Issue 9, 103703, September 2024
\nhttps:\/\/doi.org\/10.1016\/j.esmoop.2024.103703<\/a>
\nCorrigendum (in the original publication of this article the full title was not given<\/em>)
\nhttps:\/\/www.esmoopen.com\/article\/S2059-7029(24)01866-0\/fulltext<\/a><\/p>\n

\n

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial<\/h4>\n

Alexios Matikas, MD, PhD; Volker Mobus, MD, PhD; Richard Greil, MD, PhD; Anne Andersson, MD, Ph; Gunther G. Steger, MD; Michael Untch, MD, PhD; Tommy Fornander, MD, Ph; Per Malmstrom, MD, PhD; Sabine Schmatloch, MD; Hemming Johansson, BSc; Mats Hellstrom, BSc; Yvonne Brandberg, PhD; Michael Gnant, MD, PhD; Sibylle Loibl, MD, PhD; Theodoros Foukakis, MD, PhD; and Jonas Bergh, MD, PhD; on behalf of the SweBCG, ABCSG and GBG<\/p>\n

Journal of Clinical Oncology
\nJuly 17th, 2024
\nhttps:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00178<\/a><\/p>\n

\n

Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression<\/h4>\n

Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago-Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, and Michael Gnant<\/p>\n

Molecular Oncology, 12.06.2024, Online ahead of print
\nhttps:\/\/doi.org\/10.1002\/1878-0261.13671<\/a>
\nDownload<\/a><\/p>\n

\n

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B<\/h4>\n

Marm\u00e9 F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Garc\u00eda-S\u00e1enz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl S.<\/p>\n

ESMO Open. 2024 Jun 4;9(6):103466. Online ahead of print.PMID:\u00a038838498\u00a0
\nhttps:\/\/doi.org\/10.1016\/j.esmoop.2024.103466<\/a>
\nDownload<\/a><\/p>\n

\n

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy<\/h4>\n

Hatem A. Azim Jr, MD, Ph; Samuel M. Niman, MS; Ann H. Partridge, MD, MPH; Isabelle Demeestere, MD, PhD; Monica Ruggeri; Marco Colleoni, MD; Cristina Saura, MD, Ph; Chikako Shimizu, MD; Anna B. Saetersdal, MD; Judith R. Kroep, MD, PhD; Audrey Mailliez; Ellen Warner, MD; Virginia F. Borges, MD; Frederic Amant, MD; Andrea Gombos, MD; Akemi Kataoka, MD; Christine Rousset-Jablonski, MD, PhD; Simona Borstnar, MD, PhD; Junko Takei, MD; Jeong Eon Lee, MD, PhD; Janice M. Walshe, MD; Manuel Ruiz-Borrego, MD; Halle C.F. Moore, MD; Christobel Saunders, MD; Vesna Bjelic-Radisic, MD, PhD; Snezana Susnjar, MD; Fatima Cardoso, MD; Natalie J. Klar, MD; Tanja Spanic, PhD; Kathryn Ruddy, MD, MPH; Martine Piccart, MD, PhD; Larissa A. Korde, MD, MPH; Aron Goldhirsch, MD\u2020; Richard D. Gelber, PhD; Olivia Pagani, MD; and Fedro A. Peccatori, MD, PhD<\/p>\n

J Clin Oncol 00:1-11, Published May 29, 2024
\nhttps:\/\/doi.org\/10.1200\/JCO.23.02292<\/a><\/p>\n

\n

Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer – a retrospective analysis<\/h4>\n

Piringer G, Ponholzer F, Thaler J, Bachleitner-Hofmann T, Rumpold H, de Vries A, Weiss L, Greil R, Gnant M, \u00d6fner D.<\/p>\n

eCollection 2024.PMID:\u00a038817890. Front Oncol. 2024 May. 16;14:1374592.
\nhttps:\/\/doi.org\/10.3389\/fonc.2024.1374592<\/a>
\nDownload<\/a><\/p>\n

\n

The future of clinical trials – goals, ideas, and discussion<\/h4>\n

Michael Gnant, Manuela Gili, Magdalena Schwarz, Christian Fesl, Dominik Hlauschek, Anita Jallitsch-Halper, Hannes Fohler<\/p>\n

memo \u2013 Magazine of European Medical Oncology, 18.04.2024, Volume 17, 1\/2024
\nhttps:\/\/doi.org\/10.1007\/s12254-024-00969-7<\/a>
\nDownload<\/a><\/p>\n

\n

Assessing Knowledge, Competence, and Performance Following Web-Based Education on Early Breast Cancer Management: Health Care Professional Questionnaire Study and Anonymized Patient Records Analysis.<\/h4>\n

Gnant M, Abdullah KL, Boyle F, Huang CS, Bickford K, Neunie S, Noble A, Nunn A, Sproat C, Harbeck N, Barrios C<\/p>\n

JMIR Formative Research
\nPublished online: 21 March 2024
\nDOI: 10.2196\/50931. PMID: 38512328<\/p>\n

\n

Explained variation and degrees of necessity and of sufficiency for competing risks survival data.<\/h4>\n

Gleiss A, Gnant M, Schemper M<\/p>\n

Biometrical Journal Published online: 2024 Mar;66(2): e2300140
\nDOI: 10.1002\/bimj.202300140. PMID: 38409618<\/p>\n

\n

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.<\/h4>\n

Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.<\/p>\n

Annals of Oncology Published online: 2024 Feb; 35(2):159-182
\nDOI: 10.1016\/j.annonc.2023.11.016. Epub 2023 Dec 13. PMID: 38101773<\/p>\n

\n

Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?<\/h4>\n

Kerstin Wimmer, Dominik Hlauschek, Marija Balic, Georg Pfeiler, Christian F. Singer, Stefan Halper, G\u00fcnther Steger, Christoph Suppan, Simon P. Gampenrieder, Ruth Helfgott, Daniel Egle, Martin Filipits, Raimund Jakesz, Lidija S\u00f6lkner, Christian Fesl, Michael Gnant, Florian Fitzal & Richard Greil<\/p>\n

Breast Cancer Research and Treatment
\nPublished online: 25 January 2024
\nDOI: https:\/\/doi.org\/10.1007\/s10549-023-07186-6<\/a><\/p>\n

\n

Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial<\/h4>\n

Ian E. Krop, Lorenza Mittempergher, Joseph N. Paulson, Fabrice Andre, Herve Bonnefoi, Sherene Loi, Sibylle Loibl, Richard D. Gelber, Carmela Caballero, Rajith Bhaskaran, Christa Dreezen, Andrea R. Menicucci, Rener Bernards, Laura J. van\u2019t Veer, Martine J. Piccart on behalf of the APHINITY Steering Committee and Investigators<\/p>\n

JCO Precision Oncology
\nVolume\u00a08, January 18, 2024
\nhttps:\/\/doi.org\/10.1200\/PO.22.00667<\/a><\/p>\n<\/div><\/div>\n

<\/span>2023<\/div>
\n

Differential immunomodulatory effects of epirubicin\/cyclophosphamide and docetaxel in breast cancer patients<\/h4>\n

Kerstin Wimmer,\u00a0Monika Sachet,\u00a0Cristiano Ramos,\u00a0Sophie Frantal,\u00a0Hanna Birnleitner,\u00a0Christine Brostjan,\u00a0Ruth Exner,\u00a0Martin Filipits,\u00a0Zsuzsanna Bago-Horvath,\u00a0Margaretha Rudas,\u00a0Rupert Bartsch,\u00a0Michael Gnant,\u00a0Christian F. Singer,\u00a0Marija Balic,\u00a0Daniel Egle,\u00a0Rudolf Oehler\u00a0&\u00a0Florian Fitzal\u00a0<\/p>\n

Journal of Experimental & Clinical Cancer Research\u00a0volume\u00a042, Article\u00a0number:\u00a0300\u00a0(2023)\u00a0
\nPublished:\u00a014 November 2023
\nDOI: https:\/\/doi.org\/10.1186\/s13046-023-02876-x<\/a><\/p>\n

\n

ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)<\/h4>\n

Walter P. Weber MD,\u00a0Martin Heidinger MD,\u00a0Stefanie Hayoz PhD,\u00a0Zoltan Matrai MD, PhD,\u00a0Christoph Tausch MD,\u00a0Guido Henke MD,\u00a0Daniel R. Zwahlen MD,\u00a0G\u00fcnther Gruber MD,\u00a0Frank Zimmermann MD,\u00a0Giacomo Montagna MD, MPH,\u00a0Mariacarla Andreozzi PhD,\u00a0Maite Goldschmidt MSc,\u00a0Alexandra Schulz MSc,\u00a0Andreas Mueller MD,\u00a0Markus Ackerknecht PhD,\u00a0Ekaterini Christina Tampaki MD, PhD,\u00a0Vesna Bjelic-Radisic MD,\u00a0Christian Kurzeder MD,\u00a0\u00c1kos S\u00e1volt MD, PhD,\u00a0Viktor Smanyk\u00f3 MD,\u00a0Daniela Hagen MD,\u00a0Dieter J. M\u00fcller MD,\u00a0Michael Gnant MD,\u00a0Sibylle Loibl MD,\u00a0Florian Fitzal MD,\u00a0Pagona Markellou MD,\u00a0Inga Bekes MD,\u00a0Daniel Egle MD,\u00a0J\u00f6rg Heil MD\u00a0&\u00a0Michael Knauer MD, PhD\u00a0<\/p>\n

Annals of Surgical Oncology\u00a0(2023)
\nPublished: 13 November 2023
\nDOI: https:\/\/doi.org\/10.1245\/s10434-023-14489-x<\/a><\/p>\n

\n

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer<\/h4>\n

Maximilian Marhold, Simon Udovica, Anna Halstead, Mona Hirdler, Muna Ferner, Kerstin Wimmer, Zsuzsanna Bago-Horvath, Ruth Exner, Florian Fitzal, Kathrin Strasser-Weippl, Tim Robinson & Rupert Bartsch<\/p>\n

ONCOIMMUNOLOGY
\nPublished online: 13 November \u00a02023
\nDOI: https:\/\/doi.org\/10.1080\/2162402X.2023.2275846<\/a><\/p>\n

\n

Patient-reported outcomes in high-risk HR+\/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study<\/h4>\n

Jos\u00e9 Angel Garc\u00eda-S\u00e1enz, Frederik Marm\u00e9, Michael Untch, Herv\u00e9 Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole Mc Carthy, Karen Gelmon, Miguel Martin, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Ernest Law, Helen Bhattacharyya, Michael Gnant, Andreas Makris, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Sibylle Loibl, Hope S. Rugo<\/p>\n

European Journal of Cancer
\nPublished: November 5th<\/sup>, 2023
\nDOI: https:\/\/doi.org\/10.1016\/j.ejca.2023.113420<\/a><\/p>\n

\n

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.<\/h4>\n

Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Th\u00fcrlimann B;<\/p>\n

St Gallen Consensus Conference Panelists 2023.
\nAnn Oncol. 2023 Nov;34(11):970-986.
\nDOI: 10.1016\/j.annonc.2023.08.017. Epub 2023 Sep 6.PMID: 37683978
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37683978\/<\/a><\/p>\n

\n

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14\u2009324 women in 16 trials
\nEarly Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)<\/h4>\n

Lancet 2023; 401: 1277\u201392
\nDOI: https:\/\/doi.org\/10.1016\/S0140-6736(23)01082-6
\nhttps:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(23)01082-6\/fulltext<\/a>
\nOpen Access, Published: November 03, 2023<\/p>\n

\n

Impact of\u00a0Imaging\u2011Guided Localization on\u00a0Performance of\u00a0Tailored Axillary Surgery in\u00a0Patients with\u00a0Clinically Node\u2011Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC\u201103, SAKK 23\/16, IBCSG 57\u201118, ABCSG\u201153, GBG 101<\/h4>\n

Walter P. Weber, MD, Martin Heidinger, MD, Stefanie Hayoz, PhD , Zoltan Matrai, MD, PhD , Christoph Tausch, MD, Guido Henke, MD, Daniel R. Zwahlen, MD , G\u00fcnther Gruber, MD , Frank Zimmermann, MD, Giacomo Montagna, MD, MPH, Mariacarla Andreozzi, PhD, Maite Goldschmid, Alexandra Schulz, Andreas Mueller, MD, Markus Ackerknecht, PhD, Ekaterini Christina Tampaki, MD, PhD, Vesna Bjelic\u2011Radisic, MD, Christian Kurzeder, MD, \u00c1kos S\u00e1volt, MD, PhD, Viktor Smanyk\u00f3, MD, Daniela Hagen, MD, Dieter J. M\u00fcller, MD, Michael Gnant, MD, Sibylle Loibl, MD, Florian Fitzal, MD, Pagona Markellou, MD , Inga Bekes, MD , Daniel Egle, MD, J\u00f6rg Heil, MD, and Michael Knauer, MD, PhD<\/p>\n

Annals of Surgical Oncology
\nDOI: 10.1245\/s10434-023-14404-4<\/a>
\nhttps:\/\/link.springer.com\/article\/10.1245\/s10434-023-14404-4<\/a>
\nPublished 30 October 2023<\/p>\n

\n

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.<\/h4>\n

Huober J, Weder P, Ribi K, Th\u00fcrlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, M\u00fcller A, Membrez-Antonioli V, G\u00e9rard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H;<\/p>\n

Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group.<\/p>\n

JAMA Oncol. 2023 Oct 1;9(10):1381-1389.
\nDOI: 10.1001\/jamaoncol.2023.2909.PMID:\u00a037561451
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37561451\/<\/a><\/p>\n

\n

Explaining risks and benefits of loco-regional treatments to patients.<\/h4>\n

Beltran-Bless AA, Kacerovsky-Strobl S, Gnant M.Breast.<\/p>\n

2023 Oct;71:132-137. Epub 2023 Aug 22.PMID:\u00a037634470\u00a0
\nDOI: 10.1016\/j.breast.2023.08.006.
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37634470\/<\/a><\/p>\n

\n

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases\u2014a phase II study<\/h4>\n

Gudrun Piringer, Thomas Grienberger, Josef Thaler et al.<\/p>\n

https:\/\/doi.org\/10.3389\/fonc.2023.1231600<\/a>,
\nFrontiers in Oncology, 09.08.2023<\/p>\n

\n

Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer<\/h4>\n

Walter P. Weber, MD; Zoltan Matrai, MD, PhD; Stefanie Hayoz, PhD; et al
\nvon ABCSG-Seite als Co-Autoren vertreten sind F. Fitzal, M. Gnant, D. Egle<\/p>\n

JAMA Surg. Published online July 19, 2023. doi:10.1001\/jamasurg.2023.2840
\nhttps:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2807463<\/a><\/p>\n

\n

Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors: existing and emerging differences.<\/h4>\n

Johnston S, Emde A, Barrios C, Srock S, Neven P, Martin M, Cameron D, Janni W, Gnant M.<\/p>\n

JNCI Cancer Spectr. 2023 Jul 3;7(4):pkad045.
\nDOI: 10.1093\/jncics\/pkad045.PMID:\u00a037369022\u00a0
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37369022\/<\/a><\/p>\n

\n

Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).<\/h4>\n

Elfgen C, Leo C, Kubik-Huch RA, Muenst S, Schmidt N, Quinn C, McNally S, van Diest PJ, Mann RM, Bago-Horvath Z, Bernathova M, Regitnig P, Fuchsj\u00e4ger M, Schwegler-Guggemos D, Maranta M, Zehbe S, Tausch C, G\u00fcth U, Fallenberg EM, Schrading S, Kothari A, Sonnenschein M, Kampmann G, Kulka J, Tille JC, K\u00f6rner M, Decker T, Lax SF, Daniaux M, Bjelic-Radisic V, Kacerovsky-Strobl S, Condorelli R, Gnant M, Varga Z.Virchows<\/p>\n

Arch. 2023 Jul;483(1):5-20.
\nDOI: 10.1007\/s00428-023-03566-x. Epub 2023 Jun 17.PMID:\u00a037330436\u00a0
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37330436\/<\/a><\/p>\n

\n

Managing a Long and Winding Road: Estrogen Receptor-Positive Breast Cancer.<\/h4>\n

Gnant M, Turner NC, Hernando C.<\/p>\n

Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390922.
\nDOI: 10.1200\/EDBK_390922.PMID:\u00a037319380\u00a0
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37319380\/<\/a><\/p>\n

\n

Uncertainties and controversies in axillary management of patients with breast cancer.<\/h4>\n

Weber WP, Davide Gentilini O, Morrow M, Montagna G, de Boniface J, Fitzal F, Wyld L, Rubio IT, Matrai Z, King TA, Saccilotto R, Galimberti V, Maggi N, Andreozzi M, Sacchini V, Castrezana L\u00f3pez L, Loesch J, Schwab FD, Eller R, Heidinger M, Haug M, Kurzeder C, Di Micco R, Banys-Paluchowski M, Ditsch N, Harder Y, Paulinelli RR, Urban C, Benson J, Bjelic-Radisic V, Potter S, Knauer M, Thill M, Vrancken Peeters MJ, Kuemmel S, Heil J, Gulluoglu BM, Tausch C, Ganz-Blaettler U, Shaw J, Dubsky P, Poortmans P, Kaidar-Person O, K\u00fchn T, Gnant M.<\/p>\n

Cancer Treat Rev. 2023 Jun;117:102556.
\nDOI: 10.1016\/j.ctrv.2023.102556. Epub 2023 Apr 23.PMID: 37126938
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37126938\/<\/a><\/p>\n

\n

Trends in use of neoadjuvant systemic therapy in patients with clinically node\u2011positive breast cancer in Europe: prospective TAXIS study (OPBC\u201103, SAKK 23\/16, IBCSG 57\u201118, ABCSG\u201153, GBG 101)<\/h4>\n

Tausch et al
\nvon ABCSG-Seite als Co-Autoren vertreten sind F. Fitzal, M. Gnant, D. Egle, C. Hager. K. Reisenberger, C. Singer<\/p>\n

>Breast Cancer Res Treat. 2023; 201(2): 215\u2013225.<\/p>\n

Published online 2023 Jun 25. doi:\u00a010.1007\/s10549-023-06999-9<\/a><\/p>\n

\n

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer.<\/h4>\n

Bartsch R, Rinnerthaler G, Petru E, Egle D, Gnant M, Balic M, Sliwa T, Singer C.<\/p>\n

Wien Klin Wochenschr. 2024 Jun;136(11-12):347-361.
\nDOI: 10.1007\/s00508-023-02254-9. Epub 2023 Sep 8.PMID:\u00a037682349\u00a0
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37682349\/<\/a><\/p>\n

\n

Impact of BMI in Patients With Early Hormone Receptor\u2013Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial<\/h4>\n

Georg Pfeiler, Dominik Hlauschek, Erica L. Mayer\u00a0 et al<\/p>\n

DOI: 10.1200\/JCO.23.00126 Journal of Clinical Oncology
\nhttps:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.23.00126<\/a><\/p>\n

\n

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials<\/h4>\n

Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)
\nC Fesl, M Gnant, L S\u00f6lkner, G G Steger (Groups (lead investigators) contributing data)<\/p>\n

Lancet 2023 Apr 15;401(10384):1277-1292.doi: 10.1016\/S0140-6736(23)00285-4
\nhttps:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(23)00285-4\/fulltext<\/a><\/p>\n

\n

St. Gallen\/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer – A Brief Summary of the Consensus Discussion.<\/h4>\n

Balic M, Thomssen C, Gnant M, Harbeck<\/p>\n

N.Breast Care (Basel). 2023 Apr;18(3):213-222.
\nDOI: 10.1159\/000530584. Epub 2023 Apr 7.PMID:\u00a037383954\u00a0
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37383954\/<\/a><\/p>\n

\n

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer<\/h4>\n

Ann H. Partridge, M.D., M.P.H.,\u00a0Samuel M. Niman, M.S.,\u00a0Monica Ruggeri,\u00a0Fedro A. Peccatori, M.D., Ph.D.,\u00a0Hatem A. Azim, Jr., M.D., Ph.D.,\u00a0Marco Colleoni, M.D.,\u00a0Cristina Saura, M.D., Ph.D.,\u00a0Chikako Shimizu, M.D.,\u00a0Anna B. S\u00e6tersdal, M.D.,\u00a0Judith R. Kroep, M.D., Ph.D.,\u00a0Audrey Mailliez, M.D.,\u00a0Ellen Warner, M.D.,\u00a0et al., for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators\u2020<\/p>\n

The New England Journal of Medicine
\nN Engl J Med 2023; 388:1645-1656
\nDOI: 10.1056\/NEJMoa2212856<\/p>\n

IBCSG 48-14
\nhttps:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2212856?query=featured_home<\/a><\/p>\n

\n

Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment ef\ufb01cacy for early breast cancer? A sub-study of ABCSG-12<\/h4>\n

Ana-Alicia Beltran-Bless Mark J. Clemons Christian Fesl Richard Greil Gregory R. Pond Marija Balic Lisa Vandermeer Vesna Bjelic-Radisic Christian F. Singer Guenther G. Steger Ruth Helfgott Daniel Egle Lidija S\u00f6lkner Simon P. Gampenrieder Stephanie Kacerovsky-Strobl Christoph Suppan Magdalena Ritter Gabriel Rinnerthaler Georg Pfeiler Hannes Fohler Dominik Hlauschek John Hilton Michael Gnant<\/p>\n

European Journal of Cancer 180 (2023), 108-116, DOI:
\n(https:\/\/doi.org\/10.1016\/j.ejca.2022.12.003<\/a>)<\/p>\n

\n

Commentary on \u201cPrognosis according to the timing of recurrence in breast cancer\u201d.<\/h4>\n

Hlauschek D, Gnant M<\/p>\n

Ann Surg Treat Res 2023;104:1-9 Annals of Surgical Treatment and Research
\nPublished online: 2 January 2023
\nDOI: https:\/\/doi.org\/10.4174\/astr.2023.104.1.1<\/a><\/p>\n<\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":28699,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"page-publikationen.php","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-34983","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-11-14 08:25:31","action":"delete","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/34983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=34983"}],"version-history":[{"count":10,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/34983\/revisions"}],"predecessor-version":[{"id":41122,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/34983\/revisions\/41122"}],"up":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28699"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=34983"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=34983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}